4
Participants
Start Date
June 30, 2004
Study Completion Date
July 31, 2004
parecoxib/valdecoxib
parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
Pfizer Investigational Site, Buenos Aires
Pfizer Investigational Site, Buenos Aires
Lead Sponsor
Pfizer
INDUSTRY